Rodrigo Dienstmann

Active 2010–2025

92
Papers
18,894
Citations
55
h-index
83
i10-index

Citations

Citations per year for Rodrigo Dienstmann1992: 1 citations1993: 1 citations2004: 3 citations2007: 1 citations2010: 1 citations2011: 7 citations2012: 15 citations2013: 35 citations2014: 67 citations2015: 91 citations2016: 152 citations2017: 248 citations2018: 236 citations2019: 848 citations2020: 966 citations2021: 1,126 citations2022: 934 citations2023: 723 citations2024: 1,052 citations2025: 637 citations2026: 39 citations1994–2003: no citations, so these years are not shown2005–2006: no citations, so these years are not shown2008–2009: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,998 citing papers, 18.2% of this breakdownChina: 1,420 citing papers, 12.9% of this breakdownItaly: 744 citing papers, 6.8% of this breakdownUnited Kingdom: 709 citing papers, 6.5% of this breakdownGermany: 686 citing papers, 6.2% of this breakdownSpain: 555 citing papers, 5% of this breakdownFrance: 480 citing papers, 4.4% of this breakdownNetherlands: 391 citing papers, 3.6% of this breakdownJapan: 334 citing papers, 3% of this breakdownSwitzerland: 298 citing papers, 2.7% of this breakdownCanada: 270 citing papers, 2.5% of this breakdownAustralia: 244 citing papers, 2.2% of this breakdown
0%18.2%Other 26%

Fields

  • Medicine52.6%
  • Biochemistry, Genetics and Molecular Biology39.3%
  • Immunology and Microbiology2.5%
  • Computer Science1.9%
  • Chemistry0.7%
  • Neuroscience0.6%
  • Other2.4%

Topics

  • Cancer Genomics and Diagnostics7.3%
  • Colorectal Cancer Treatments and Studies5.8%
  • Genetic factors in colorectal cancer5.3%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Cancer Cells and Metastasis3%
  • Lung Cancer Treatments and Mutations2.5%
  • Other71.3%

Coauthors

All papers

Open in search
  1. The consensus molecular subtypes of colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , René Bernards, Stephen Friend, Pierre Laurent‐Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk F.A. Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar - Nature Medicine 2015 cited by 5,259

  2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 1,188

  3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Authors: , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 787

  4. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    Authors: , , , , , - Nature reviews. Cancer 2017 cited by 1,030

  5. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 210

  6. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason Walker, Benjamin M. Good, Chunlei Wu, Andrew I. Su, Rodrigo Dienstmann, Adam A. Margolin, David Tamborero, Núria López-Bigas, Steven J.M. Jones, Ron Bose, David H. Spencer, Lukas D. Wartman, Richard K. Wilson, Elaine R. Mardis, Obi L. Griffith - Nature Genetics 2017 cited by 674

  7. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J. O’Connor, Orland Dı́ez, Judith Balmañà, Violeta Serra - EMBO Molecular Medicine 2018 cited by 274

  8. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paolo Nucíforo, Rodrigo Dienstmann, Chandra Verma, Núria López-Bigas, Maurizio Scaltriti, Mónica Arnedos, Cristina Saura, Violeta Serra - Nature Communications 2022 cited by 120

  9. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

    Authors: , , , , , , , , , , , , , , - European Radiology 2020 cited by 205

  10. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valentina Fornerone, Paola Gabaldi, Felix Haglund, Johan Hartman, Peter Horak, Tanja Jutzi, Mary Kasanicki, Simon Kreutzfeldt, Lucian Le Cornet, Rolf Lewensohn, Johan Lindberg, Carlos López, Andreas Lundqvist, Jose‐Ezequiel Martín, Gerrit A. Meijer, Susana Muñoz, Maud Ngo Camus, Claudio Nicotra, Paolo Nucíforo, Petra Oberrauch, Päivi Östling, Laura Pelz, Alejandro Piris‐Giménez, Elena Provenzano, Étienne Rouleau, John Rowell, Omar Saavedra, Giovanni Scoazec, Kenneth B. Seamon, Marc Tischkowitz, Lizet van der Kolk, Ruud van der Noll, María Vieito, Daniël J. Vis, Ana Vivancos, Christina von Gertten, Anders Wennborg, Lodewyk F.A. Wessels, Valtteri Wirta, Judith Balmañà, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile E. Voest, Jordi Rodón, Janne Lehtiö - Nature Cancer 2022 cited by 130

  11. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 111

  12. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 150

  13. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

    Authors: , , , , , , , , , - Annals of Oncology 2013 cited by 366

  14. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Bardelli, Josep Tabernero - JAMA Oncology 2018 cited by 144

  15. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

    Authors: , , , , , , , , - Clinical Cancer Research 2018 cited by 422

  16. Development of PI3K inhibitors: lessons learned from early clinical trials

    Authors: , , , - Nature Reviews Clinical Oncology 2013 cited by 766

  17. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joaquı́n Mateo, Joaquı́n Arribas, Rodrigo Dienstmann, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Sara Gutiérrez‐Enríquez, Judith Balmañà, Violeta Serra - Cancer Research 2022 cited by 97

  18. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

    Authors: , , , - Molecular Cancer Therapeutics 2014 cited by 465

  19. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

    Authors: , , , , , , , , , - Annals of Oncology 2019 cited by 266

  20. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raquel Pérez-López - Radiology 2021 cited by 105

  21. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 101

  22. Early-Stage Breast Cancer Detection in Breast Milk

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2023 cited by 58

  23. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan M. Mockus, Olivier Elemento, Nikolaus Schultz, Núria López-Bigas, Mark Lawler, Jeremy Goecks, Malachi Griffith, Obi L. Griffith, Adam A. Margolin - Nature Genetics 2020 cited by 176

  24. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 cited by 65